CHD1L and neoplasm: Furthermore, our results show that inhibiting CHD1L with OTI-611 can reprogram chemo/targeted therapy-induced G2/M arrest into G1 arrest in a dose-dependent manner, disrupting cell cycle progression and proliferation to kill tumor cells.